CVSG
Fiscal year ends June Quarters are offset from the calendar — Q1 is Jul–Sep

CVS Group plc is a holding company that operates an integrated veterinary services business in the UK and Australia. The group provides clinical care through a network of veterinary practices, including specialist-led referral hospitals, dedicated out-of-hours sites, equine practices, and farm practices. Its business segments include Veterinary Practices, Laboratories providing diagnostic services, Buying Groups, a pet health plan, and an online retail business. Key brands and services include VetDirect, The Healthy Pet Club, and Animed Direct. The company serves pet owners, farmers, and equestrian clients, offering preventative care, complex clinical treatments, and diagnostic testing. CVS Group was established in 1999.

Summarised from the company's own disclosures, fiscal year ended Jun 2026

Industry Medical Care Facilities Homepage cvsukltd.co.uk
Sector Healthcare IR page cvsukltd.co.uk/investor-centre
Tags
veterinary care, animal diagnostics, equine medicine, farm animal health, pet health plans, veterinary retail, referral hospitals, out-of-hours clinics, VetDirect, The Healthy Pet Club, Animed Direct
Press page —

Metrics

Valuation  
Market cap £ 842.726M
Market cap (USD) $ 1.115B
P/E 4.99
PEG —
P/BV 0.29
P/S 0.12
P/OCF 1.18
P/FCF 1.97
Dividend yield —
Turnover / mcap —
Returns  
ROE 6.0%
ROI 4.9%
ROIC 7.2%
Profit margin 2.5%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y —
Earnings growth 3y (net profit CAGR) -25.5%
Quality  
Profitable Yes
Margin expanding No
Buying back stock Yes
Diluting (TTM) No
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 0
Quality score 47.1%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Revenue 7.128B 6.732B 638.7M 608.3M 554.2M — 427.8M 406.5M 327.3M 271.8M 218.1M 167.3M 142.9M 120.1M 108.7M — 85.527M 76.605M
Net profit 178M 530M 6.4M 419M 25.7M — 5.7M 8.2M 10.7M 11.5M 7M 6.8M 4.8M 4M 2.9M — — —
Free cash flow 428M 557M — — — — — — — — — — — — — — — —

Figure FY 2026 FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009
Share price 12.7 12.16 10.19 17.5 16.18 18.08 — — — — — — — — — — — —
Price performance 12m 0.04 0.19 -0.42 0.08 -0.11 — — — — — — — — — — — — —

Filed figures

Figure Jun 2024 Jun 2025 Jun 2026
Balance sheet detail
Lease liabilities (GBP) — 1.04B 1.06B
Cash and deposits (GBP) 165M 161M 184M
Right-of-use assets (GBP) — 984M 996M
Cash flow detail
Operating cash flow (GBP) — 821M 713M
Purchases of property, plant and equipment (GBP) — -264M -285M
Purchases of intangible assets (GBP) — -78M -79M
Dividends paid (cash effect) (GBP) — -57M -61M
Share buybacks (cash effect) (GBP) — 0.00 -317M
Interest paid (cash effect) (GBP) — -165M -158M
Income taxes paid (cash effect) (GBP) — -155M -161M
Free cash flow (OCF - PPE - intangibles) (GBP) — 479M 349M
Income detail
Total comprehensive income (GBP) — 439M 281M
Comprehensive income to owners (GBP) — 436M 274M
Reported Oct 6, 2026 Oct 6, 2026 Oct 6, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Total Voting Rights Bull 0 Bear 0 Routine

CVS, the UK listed veterinary group and a leading provider of veterinary services, announces that, as of 30 October 2026, following cancellation of the Ordinary Shares purchased pursuant to the Company's share buyback programme (announced on 26 May 2026) prior to the date of this announcement, the Company's total issued share capital consists of 66,725,634 ordinary shares of 0.2p each ("Ordinary Shares").

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure Guidance and Transparency Rules.

Transaction in Own Shares Bull 1 Bear 0 Routine

CVS announces that it purchased the following number of its ordinary shares of 0.2 pence each (“Ordinary Shares”) from Joh. Berenberg, Gossler & Co. KG, London Branch (”Berenberg”), in accordance with the terms of the share buyback programme announced on 26 May 2026 (the "Share Buyback Programme").

Date of purchases: 19/10/2026 – 23/10/2026
Aggregate number of Ordinary Shares purchased: 150,000
Lowest price paid per share (GBp): 1,272.00
Highest price paid per share (GBp): 1,322.00
Volume weighted average price paid per share (GBp): 1,303.07

CVS intends to cancel all of the purchased Ordinary Shares.

Following settlement of the above purchases and cancellation of the Ordinary Shares purchased, CVS will have 66,830,249 Ordinary Shares in issue and holds no Ordinary Shares in treasury.

The total number of voting rights in CVS is therefore 66,830,249 and this figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, CVS under the Financial Conduct Authority's Disclosure and Transparency Rules.

Since the commencement of the Share Buyback Programme, the Company has repurchased 3,332,850 Ordinary Shares in aggregate at a weighted average price of 1,248.1 pence per share.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 (the Market Abuse Regulation), as it forms part of Retained EU Law as defined in the European Union (Withdrawal) Act 2018, (a full breakdown of the individual trades made by Berenberg as part of the Share Buyback Programme is attached to this announcement).

http://www.rns-pdf.londonstockexchange.com/rns/3158A_1-2026-10-23.pdf

Contacts
CVS Group plc via FGS Global
Richard Fairman, Chief Executive Officer
Robin Alfonso, Chief Financial Officer
Paul Higgs, Chief Veterinary Officer
Charlotte Page, Head of Investor Relations
FGS Global
Faeth Birch +44 (0)207 251 3801
Charlie Chichester [email protected]

About CVS Group plc (www.cvsukltd.co.uk)

CVS Group is a leading provider of veterinary services, operating in the UK and Australia, listed on the Main Market of the London Stock Exchange.  CVS is focused on providing high-quality clinical services to its clients and their animals, with outstanding and dedicated clinical teams and support colleagues at the core of its strategy.

The Group operates over 475 veterinary practices across its two territories, including specialist referral hospitals and dedicated out-of-hours sites. Alongside the core Veterinary Practices division, CVS operates Laboratories (providing diagnostic services to CVS and third-parties) and an online retail business ("Animed Direct").

The Group employs 9,000 personnel, including 2,500 veterinary surgeons and 3,300 nurses.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com .

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy .

END

POSPPGRGUUPQGQW

Posting of Annual Report and Notice of AGM Bull 0 Bear 0 Routine

RNS Number : 1185A

CVS Group plc

23 October 2026

23 October 2026

CVS Group plc

(“CVS” or the “Company”)

Posting of Annual Report and Notice of Annual General Meeting

CVS, the UK listed veterinary group and a leading provider of veterinary services, announces that its Annual General Meeting ("AGM") will be held at the offices of Linklaters LLP at 20 Ropemaker Street, London EC2Y 8HQ on 25 November 2026 at 11:00am.

The Annual Report and Accounts for the financial year ended 30 June 2026 (the "Annual Report"), the Notice of AGM and proxy form were sent on 23 October 2026 to those shareholders who have requested hard copies.  Shareholders who have elected to receive shareholder information electronically have been notified that the Annual Report and Notice of AGM are available on the Company's website at: https://www.cvsukltd.co.uk/investor-centre, and the forms of proxy are available to shareholders on request by contacting [email protected] .

In accordance with UK Listing Rule 6.4.1, copies of the Annual Report and the Notice of AGM have also been uploaded to the National Storage Mechanism and will be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

The AGM will be held as a physical meeting. The Company encourages shareholders to submit a proxy vote in advance of the AGM. Full details of voting arrangements are contained in the Notice of AGM.

The result of the AGM will be announced shortly after its conclusion and published on the Company’s website.

Stamp Duty Reserve Tax (“SDRT”) and UK Listing Relief

Information regarding the Company's eligibility for UK Listing Relief from SDRT, and guidance for shareholders who wish to seek repayment of SDRT from HMRC in respect of transactions from 29 January 2026 to 24 September 2026 is available in the Investor Centre section of the Company's website (https://www.cvsukltd.co.uk/investor-centre/stamp-duty-reserve-tax-and-uk-listing-relief/).

Prompts

CVS Group plc (ticker CVSG), listed in United Kingdom.

ETFs Holding CVS Group plc

ETF Weight in ETF Shares Market value As of
AVDS 0.05% 9,168 $ 169.27K Nov 16, 2026
DFIS 0.04% 136,322 $ 2.543M Nov 12, 2026
AVDE 0.01% 61,117 $ 1.128M Nov 16, 2026